HRP20191277T8 - Anti-cd26 antitijela i njihove primjene - Google Patents

Anti-cd26 antitijela i njihove primjene

Info

Publication number
HRP20191277T8
HRP20191277T8 HRP20191277T HRP20191277T8 HR P20191277 T8 HRP20191277 T8 HR P20191277T8 HR P20191277 T HRP20191277 T HR P20191277T HR P20191277 T8 HRP20191277 T8 HR P20191277T8
Authority
HR
Croatia
Prior art keywords
antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Naro Antonio Francesco Di
Original Assignee
Adienne S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48092884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191277(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adienne S A filed Critical Adienne S A
Publication of HRP20191277T1 publication Critical patent/HRP20191277T1/hr
Publication of HRP20191277T8 publication Critical patent/HRP20191277T8/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20191277T 2013-02-19 2019-07-17 Anti-cd26 antitijela i njihove primjene HRP20191277T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13425029.9A EP2767549A1 (en) 2013-02-19 2013-02-19 Anti-CD26 antibodies and uses thereof
PCT/EP2014/053243 WO2014128168A1 (en) 2013-02-19 2014-02-19 Anti-cd26 antibodies and uses thereof
EP14705767.3A EP2864359B1 (en) 2013-02-19 2014-02-19 Anti-cd26 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
HRP20191277T1 HRP20191277T1 (hr) 2019-10-18
HRP20191277T8 true HRP20191277T8 (hr) 2019-11-01

Family

ID=48092884

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191277T HRP20191277T8 (hr) 2013-02-19 2019-07-17 Anti-cd26 antitijela i njihove primjene

Country Status (26)

Country Link
US (2) US9376498B2 (hr)
EP (3) EP2767549A1 (hr)
JP (2) JP6240195B2 (hr)
KR (1) KR101869589B1 (hr)
CN (1) CN104684931B (hr)
AU (1) AU2014220777B2 (hr)
CA (1) CA2874422C (hr)
CY (1) CY1121980T1 (hr)
DK (1) DK2864359T3 (hr)
ES (1) ES2738283T3 (hr)
HK (1) HK1205151A1 (hr)
HR (1) HRP20191277T8 (hr)
HU (1) HUE045150T2 (hr)
IL (1) IL237244B (hr)
LT (1) LT2864359T (hr)
ME (1) ME03753B (hr)
MX (1) MX357293B (hr)
NZ (1) NZ631111A (hr)
PL (1) PL2864359T3 (hr)
PT (1) PT2864359T (hr)
RS (1) RS59093B1 (hr)
RU (1) RU2662933C2 (hr)
SA (1) SA515360248B1 (hr)
SI (1) SI2864359T1 (hr)
TR (1) TR201910572T4 (hr)
WO (1) WO2014128168A1 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11242399B2 (en) * 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US10630229B2 (en) * 2016-10-11 2020-04-21 Kevin Stapleton Panel mounting bracket with grounding mid-clamp and related methods
KR101960414B1 (ko) * 2016-11-11 2019-03-27 대한민국 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도
BR112020012388A2 (pt) * 2017-12-22 2020-11-24 Adienne S.A. método para a determinação in vitro da potência de um ligante anti-cd26
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
WO2022023792A1 (en) * 2020-07-28 2022-02-03 Adienne S.A. Treatment of idiopathic inflammatory myopathies
AU2022271679A1 (en) * 2021-05-13 2023-12-07 Adienne S.A. Methods of treating graft versus host disease
EP4337692A2 (en) * 2021-05-13 2024-03-20 Adienne S.A. Methods of treating dermatomyositis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
NL9400309A (nl) * 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
EP1241179B1 (en) 1998-04-15 2006-08-02 Genentech, Inc. Human protein having in vitro antiproliferative activity
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
AU2002308637B2 (en) * 2001-05-11 2007-05-17 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
RU2486204C2 (ru) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
KR101352588B1 (ko) * 2005-09-14 2014-01-17 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료용 디펩티딜 펩티다아제 억제제
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
RU2331881C1 (ru) * 2007-03-09 2008-08-20 ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ определения риска развития атопических заболеваний у новорожденных детей
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
KR20190017065A (ko) * 2010-08-18 2019-02-19 테레사 데이셔 림프양 조직에 줄기 세포와 조상 세포 결합을 저해하고, 그리고 림프 조직에서 배 중심을 재생하기 위한 조성물과 방법
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof

Also Published As

Publication number Publication date
RU2662933C2 (ru) 2018-07-31
CA2874422C (en) 2021-10-19
AU2014220777B2 (en) 2017-03-16
CN104684931A (zh) 2015-06-03
ES2738283T3 (es) 2020-01-21
CY1121980T1 (el) 2020-10-14
JP2017221205A (ja) 2017-12-21
NZ631111A (en) 2017-06-30
EP2864359B1 (en) 2019-04-24
CA2874422A1 (en) 2014-08-28
DK2864359T3 (da) 2019-07-22
US20150017178A1 (en) 2015-01-15
TR201910572T4 (tr) 2019-08-21
BR112015002130A2 (pt) 2017-11-07
MX357293B (es) 2018-07-04
LT2864359T (lt) 2019-09-25
US10208126B2 (en) 2019-02-19
KR20150023419A (ko) 2015-03-05
EP2864359A1 (en) 2015-04-29
EP3536711A1 (en) 2019-09-11
MX2014014935A (es) 2015-06-17
SI2864359T1 (sl) 2019-09-30
KR101869589B1 (ko) 2018-06-20
HRP20191277T1 (hr) 2019-10-18
PL2864359T3 (pl) 2019-11-29
RS59093B1 (sr) 2019-09-30
CN104684931B (zh) 2019-08-27
ME03753B (me) 2021-04-20
HUE045150T2 (hu) 2019-12-30
PT2864359T (pt) 2019-07-26
AU2014220777A1 (en) 2014-11-27
RU2014153440A (ru) 2016-07-20
JP6240195B2 (ja) 2017-11-29
IL237244A0 (en) 2015-04-30
HK1205151A1 (en) 2015-12-11
US9376498B2 (en) 2016-06-28
JP2015529204A (ja) 2015-10-05
WO2014128168A1 (en) 2014-08-28
EP2767549A1 (en) 2014-08-20
SA515360248B1 (ar) 2017-02-20
US20160264676A1 (en) 2016-09-15
IL237244B (en) 2019-09-26

Similar Documents

Publication Publication Date Title
IL261743B (en) and their uses 33–il antibodies against
HK1232243A1 (zh) 抗- 抗體及其用途
IL261547B (en) Antibodies against pesidine and their uses
HK1214969A1 (zh) 抗- -β抗體及其使用
IL243974A0 (en) Antibodies against -prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
HK1223544A1 (zh) 抗體製劑和方法
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
HRP20191277T8 (hr) Anti-cd26 antitijela i njihove primjene
GB201309178D0 (en) Enzyme and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201305297D0 (en) Novel agents and uses thereof